0001683168-24-001399.txt : 20240308 0001683168-24-001399.hdr.sgml : 20240308 20240308162918 ACCESSION NUMBER: 0001683168-24-001399 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240308 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240308 DATE AS OF CHANGE: 20240308 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sonoma Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001367083 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 680423298 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33216 FILM NUMBER: 24734821 BUSINESS ADDRESS: STREET 1: 5445 CONESTOGA COURT, SUITE 150 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 800-759-9305 MAIL ADDRESS: STREET 1: 5445 CONESTOGA COURT, SUITE 150 CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: Oculus Innovative Sciences, Inc. DATE OF NAME CHANGE: 20060622 8-K 1 sonoma_8k.htm CURRENT REPORT
false 0001367083 0001367083 2024-03-08 2024-03-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) March 8, 2024

 

SONOMA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-33216   68-0423298
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

5445 Conestoga Court, Suite 150

Boulder, CO 80301

(Address of principal executive offices)

(Zip Code)

 

(800) 759-9305

(Registrant’s telephone number, including area code)

 

Not applicable.

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock SNOA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

   

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

As previously disclosed, on December 15, 2023, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”), with Maxim Group LLC (“Maxim”), pursuant to which the Company may offer and sell, from time to time, through Maxim, as sales agent or principal, shares of its common stock, $0.0001 par value per share. On March 8, 2024, the Company entered into an amendment to the Agreement (“Amendment No. 1”) to provide for the sale of up to $785,679 of additional shares under the Agreement.

 

Sales of shares of common stock under the Agreement, as amended by Amendment No. 1, will be made pursuant to the registration statement on Form S-3 (File No. 333-275311), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on November 20, 2023, and a related prospectus supplement filed with the SEC on March 8, 2024, for an aggregate offering price of up to $785,679.

 

The foregoing summary of Amendment No. 1 and the original Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of Amendment No. 1, which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K, and the original Agreement, which was filed as Exhibit 1.1 to the Company’s Current Report on Form 8-K on December 18, 2023.

 

A copy of the opinion of Burns & Levinson, LLP relating to the legality of the issuance and sale of shares under the Agreement, as amended by Amendment No. 1, is attached hereto as Exhibit 5.1 to this Current Report on Form 8-K.

 

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any shares under the Agreement, nor shall there be any sale of such shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

 

This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s future activities, or future events or conditions. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company’s Annual Report on Form 10-K and in other documents that the Company files from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit Number   Description
1.1*   Amendment No. 1 to Equity Distribution Agreement, by and between Sonoma Pharmaceuticals, Inc. and Maxim Group LLC., dated March 8, 2024.
1.2   Equity Distribution Agreement, by and between Sonoma Pharmaceuticals, Inc. and Maxim Group LLC., dated December 15, 2023 (included as Exhibit 1.1 to the Company’s Current Report on Form 8-K filed on December 18, 2023, and incorporated herein by reference).
5.1*   Opinion of Burns & Levinson, LLP
23.1   Consent of Burns & Levinson, LLP (included in Exhibit 5.1).
104   Cover Page Interactive Data File (formatted in Inline XBRL in Exhibit 101).

 

* Filed herewith.

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SONOMA PHARMACEUTICALS, INC.
   
   
Date: March 8, 2024 By:  /s/ Amy Trombly
 

Name:

Title:

 Amy Trombly
Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

 EX-1.1 2 sonoma_ex0101.htm AMENDMENT NO. 1 TO EQUITY DISTRIBUTION AGREEMENT

Exhibit 1.1

 

AMENDMENT NO. 1

TO

EQUITY DISTRIBUTION AGREEMENT

 

March 8, 2024

 

Maxim Group LLC

300 Park Avenue, 16th Floor

New York, New York 10022

 

Ladies and Gentlemen:

 

Sonoma Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Maxim Group LLC, as sales agent (the “Agent”), are parties to that certain Equity Distribution Agreement dated as of December 15, 2023 (the “Original Agreement”). The Company and the Agent desire to amend the Original Agreement as set forth in this agreement (this “Amendment No. 1”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, intending to be legally bound, hereby amend the Original Agreement as follows:

 

1.Section 2(d) is hereby deleted and replaced in its entirety with the following:

 

“(d) The Company and the Agent agree that beginning as of the date of the Original Agreement, the Agent was not, and shall not be, required to sell any certain number of shares or dollar amount of Common Stock, whether based on the daily trading volume of the Common Stock or otherwise, and that the Agent will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell any such Shares on the Company’s behalf as requested to be sold by the Company, subject to the conditions set forth in the Original Agreement and applicable law.”

 

2.Section 3(dd) is hereby deleted and replaced in its entirety with the following:

 

“(dd) The parties hereto are also party to that certain Placement Agency Agreement, dated October 30, 2023 (the “2023 Placement Agency Agreement”). The Company and the Agent agree that the Agent hereby provides a one-time waiver of Section 4(q) of the 2023 Placement Agency Agreement for any Shares sold under this Agreement pursuant to the prospectus, dated March 8, 2024, with respect to up to $785,679 of shares of Common Stock. Except as specifically set forth herein, the terms set forth in the 2023 Placement Agency Agreement shall continue to apply as set forth therein.”

 

3.No Other Changes. Except as specifically set forth herein, all other provisions of the Original Agreement shall remain in full force and effect.
   
4.Entire Agreement; Amendment; Severability; Headings. This Amendment No. 1 together with the Original Agreement (including all schedules and exhibits attached hereto and transaction notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Amendment No. 1 together with the Original Agreement nor any term hereof or thereof may be amended except pursuant to a written instrument executed by the Company and the Agent. In the event that any one or more of the provisions contained herein or therein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Amendment No. 1 together with the Original Agreement. All references in the Original Agreement to the “Agreement” shall mean the Original Agreement as amended by this Amendment No. 1; provided, however, that all references to “date of this Agreement” in the Original Agreement shall continue to refer to the date of the Original Agreement.

 

 

 

 1 

 

 

5.Governing Law. This Amendment No. 1 shall be governed by and construed in accordance with the laws of the State of New York, including Section 5-1401 of the General Obligations Law of the State of New York, but otherwise without regard to conflict of laws rules that would apply the laws of any other jurisdiction.
   
6.Counterparts. This Amendment No. 1 may be executed in one or more counterparts and, if executed in more than one counterpart, the executed counterparts shall each be deemed to be an original and all such counterparts shall together constitute one and the same instrument. In the event that any signature is delivered by facsimile transmission or a .pdf or other electronic format file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or .pdf or other electronic signature page were an original thereof. 
   
7.Waiver of Jury Trial. Each of the Company and the Agent hereby waives any right it may have to a trial by jury in respect of any claim based upon or arising out of this Amendment No. 1 or the transactions contemplated hereby.
   
8.Submission to Jurisdiction. The Company irrevocably submits to the non-exclusive jurisdiction of any New York State or United States federal court sitting in The City of New York, Borough of Manhattan, over any suit, action or proceeding arising out of or relating to this Agreement, the Prospectus, the Registration Statement, or the offering of the Shares. The Company irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of venue of any such suit, action or proceeding brought in such a court and any claim that any such suit, action or proceeding brought in such a court has been brought in an inconvenient forum. To the extent that the Company has or hereafter may acquire any immunity (on the grounds of sovereignty or otherwise) from the jurisdiction of any court or from any legal process with respect to itself or its property, the Company irrevocably waives, to the fullest extent permitted by law, such immunity in respect of any such suit, action or proceeding including without limitation, any immunity pursuant to the U.S. Foreign Sovereign Immunities Act of 1976, as amended. Each of the Agent and the Company further agrees to accept and acknowledge service of any and all process which may be served in any such suit, action or proceeding in the Supreme Court of the State of New York, New York County, or in the United States District Court for the Southern District of New York and agrees that service of process upon the Company mailed by certified mail or delivered by Federal Express via overnight delivery to the Company’s address shall be deemed in every respect effective service of process upon the Company in any such suit, action or proceeding, and service of process upon the Agent mailed by certified mail or delivered by Federal Express via overnight delivery to the Agent’s address shall be deemed in every respect effective service of process upon such Agent in any such suit, action or proceeding.

 

[Signature Page Follows]

 

 

 

 

 

 2 

 

 

If the foregoing is in accordance with your understanding of our agreement, please sign and return to the Company the enclosed duplicate of this Amendment No. 1 to Original Agreement, whereupon this letter and your acceptance shall represent a binding agreement between the Company and the Agent in accordance with its terms.

 

  Very truly yours,
     
     
  SONOMA PHARMACEUTICALS, INC.
     
     
  By: /s/ Amy Trombly
    Name: Amy Trombly
    Title: President and Chief Executive Officer

 

 

Confirmed as of the date first above mentioned.

 

MAXIM GROUP LLC, as Agent  
     
By: /s/ Clifford A. Teller  
  Name: Clifford A. Teller  
  Title: Co-President  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature Page to Amendment No. 1 to the Equity Distribution Agreement]

 

 

 

 3 

 

 EX-5.1 3 sonoma_ex0501.htm OPINION

Exhibit 5.1

 

 

 

March 8, 2024

 

Sonoma Pharmaceuticals, Inc.

5445 Conestoga Court

Suite 150

Boulder, CO 80301

 

Dear Ladies and Gentlemen:

 

We have acted as legal counsel to Sonoma Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the offering and sale by the Company of shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), having an aggregate offering price of up to $785,679 to be offered and sold from time to time pursuant to a prospectus supplement dated March 8, 2024 (the “Prospectus Supplement”) and the accompanying prospectus dated November 22, 2023 (together with the Prospectus Supplement, the “Prospectus”) that form part of the Company’s registration statement on Form S-3 (File No. 333-275311) (together with the Prospectus, the “Registration Statement”) filed by the Company with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”). The Shares are to be sold by the Company through or to Maxim Group LLC (the “Sales Agent”), as sales agent and/or principal, in accordance with that certain Equity Distribution Agreement, dated December 15, 2023 and as amended on March 8, 2024 by and between the Company and the Sales Agent (the “Equity Distribution Agreement”), as described in the Prospectus Supplement.

 

In connection with this opinion, we have examined originals or copies, certified or otherwise identified to our satisfaction, of (i) the Registration Statement, including the Prospectus Supplement, (ii) a specimen certificate representing the Common Stock, (iii) the Equity Distribution Agreement, (iv) the Company’s Restated Certificate of Incorporation, as currently in effect, (v) the Company’s Bylaws, as currently in effect, and (vi) certain resolutions adopted by the Board of Directors of the Company and committees thereof with respect to the Equity Distribution Agreement and the issuance of the Shares. We have also examined originals or copies, certified or otherwise identified to our satisfaction, of such records of the Company and such agreements, certificates of public officials, certificates of officers or other representatives of the Company and others, and such other documents, certificates and records, as we have deemed necessary or appropriate as a basis for the opinion set forth herein.

  

In our examination, we have assumed and have not verified (i) the legal capacity of all natural persons, (ii) the genuineness of all signatures, (iii) the authenticity of all documents submitted to us as originals, (iv) the conformity with the originals of all documents supplied to us as copies, (v) the accuracy and completeness of all corporate records and documents made available to us by the Company, (vi) the truth, accuracy and completeness of the information, representations and warranties contained in the records, documents, instruments and certificates we have reviewed; and (vii) that the foregoing documents, in the form submitted to us for our review, have not been altered or amended in any respect material to our opinion stated herein. We have relied as to factual matters upon certificates from officers of the Company and certificates and other documents from public officials and government agencies and departments and we have assumed the accuracy and authenticity of such certificates and documents. We have further assumed that the Shares will be issued and delivered in accordance with the terms of the Equity Distribution Agreement.

 

 

 

 1 

 

 

For purposes of the opinion set forth below, we refer to the following as “Future Approval and Issuance”: (a) the approval by the Company’s board of directors (or a duly authorized committee of the board of directors) of the issuance of the Shares (the “Approval”) and (b) the issuance of the Shares in accordance with the Approval and the receipt by the Company of the consideration (which shall not be less than the par value of such Shares) to be paid therefor in accordance with the Approval.

 

Based on the foregoing, and subject to the assumptions, qualifications and limitations set forth herein, as of the date hereof, we are of the opinion that the Shares have been duly authorized for issuance, and upon Future Approval and Issuance, will be validly issued, fully paid and non-assessable.

 

For purposes of our opinion above, we express no opinion as to the law of any jurisdiction other than the General Corporation Law of the State of Delaware (including the statutory provisions, all applicable provisions of the Delaware Constitution and reported judicial decisions interpreting the foregoing). No opinion is expressed herein with respect to the qualification of the Shares under the securities or blue sky laws of any state or foreign jurisdiction. The opinion expressed herein is given as of this date, and we do not undertake to supplement this opinion with respect to any events or changes occurring subsequent to the date hereof.

  

We hereby consent to the filing of this opinion as an exhibit to the Current Report on Form 8-K to be filed with the Commission in connection with the offering and to the use of our name under the caption “Legal Matters” in the Prospectus Supplement. In giving this consent, we do not thereby admit that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

 

 

  Very truly yours,
   
  /s/ Burns & Levinson LLP
   
  Burns & Levinson LLP

 

 

 

 

 

 

 2 

 

 EX-101.SCH 4 snoa-20240308.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 snoa-20240308_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 snoa-20240308_pre.xml XBRL PRESENTATION FILE GRAPHIC 7 image_001.jpg GRAPHIC begin 644 image_001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 08, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 08, 2024
Entity File Number 001-33216
Entity Registrant Name SONOMA PHARMACEUTICALS, INC.
Entity Central Index Key 0001367083
Entity Tax Identification Number 68-0423298
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 5445 Conestoga Court
Entity Address, Address Line Two Suite 150
Entity Address, City or Town Boulder
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80301
City Area Code (800)
Local Phone Number 759-9305
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol SNOA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sonomapharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports snoa-20240308.xsd snoa-20240308_lab.xml snoa-20240308_pre.xml sonoma_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sonoma_8k.htm": { "nsprefix": "SNOA", "nsuri": "http://sonomapharma.com/20240308", "dts": { "schema": { "local": [ "snoa-20240308.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "snoa-20240308_lab.xml" ] }, "presentationLink": { "local": [ "snoa-20240308_pre.xml" ] }, "inline": { "local": [ "sonoma_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://sonomapharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001683168-24-001399-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-24-001399-xbrl.zip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sonoma_8k_htm.xml IDEA: XBRL DOCUMENT 0001367083 2024-03-08 2024-03-08 iso4217:USD shares iso4217:USD shares false 0001367083 8-K 2024-03-08 SONOMA PHARMACEUTICALS, INC. DE 001-33216 68-0423298 5445 Conestoga Court Suite 150 Boulder CO 80301 (800) 759-9305 false false false false Common Stock SNOA NASDAQ false